摘要
为评价PEG-rhG-CSF预防恶性浆膜腔内化疗后中性粒细胞减少的可行性、安全性.选择合并恶性浆膜腔积液的恶性肿瘤患者126例实施PEG-rhG-CSF皮下注射的单臂实验研究.结果显示:患者中无因为发生ANC减少而导致死亡发生,未见严重的血小板、肝脏、肾脏毒性反应.可见浆膜腔内化疗后给予PEG-rhG-CSF皮下注射可以很好的预防中性粒细胞减少,具有明确的治疗疗效,临床安全性稳定.
To evaluate the feasibility and safety of PEG-rhG-CSF in preventing neutropenia after malignant serosal cavity chemotherapy,one-arm experiment was carried out in 126 patients with malignant tumor complicated with serosal fluid.The results indicate as follow:none of the patients died as a result of the ANC reduction;no serious platelet,liver or renal toxicity was observed.Therefore,subcutaneous injection of PEG-RHG-CSF after serosal cavity chemotherapy can effectively prevent neutropenia,with definite therapeutic effect and stable clinical safety.
作者
王思源
张素琴
陈盛阳
王武龙
黄剑辉
高文斌
WANG Si-yuan;ZHANG Su-qing;CHEN Sheng-yang;WANG Wu-long;HUANG Jian-hui;GAO Wen-bin(Department of Oncology,The Third Affiliated Hospital of Shenzhen University,Shenzhen 518001,Guangdong,China;Post-Graduate School of Medicine,Shenzhen University,Shenzhen 518071,Guangdong,China;Department of Pharmacy,The Third Affiliated Hospital of Shenzhen University,Shenzhen 518001,Guangdong,China;Department of Oncology,The Second Affiliated Hospital of Baotou Medical College,Inner Mongolia University of Science and Technology,Baotou 014030,Inner Mongolia,China;Department of Oncology,Lishui Hospital of Zhejiang University,Lishui 323000,Zhejiang,China)
出处
《韶关学院学报》
2020年第9期45-47,共3页
Journal of Shaoguan University
基金
CSCO-齐鲁肿瘤研究基金研究项目(Y-Q201801-007)
深圳市罗湖区软科学研究计划项目(2018-68,2018-69).
